Please login to the form below

Not currently logged in
Email:
Password:

LionsDen Communications Award for Excellence in Payer and Policymaker Engagement

Sponsored by

Finalist

Osteosarcoma – rewriting the rule book

Takeda UK in association with Liberation Communications


Summary of work

Mepact (mifamurtide) is the first advance in osteosarcoma treatment for more than 20 years. A very rare form of bone cancer, osteosarcoma is highly aggressive with a propensity to metastasise, affecting around 150 children and young adults each year across the UK.

Before Mepact a third of all children and young adults diagnosed with osteosarcoma did not survive. With Mepact up to an estimated additional 12 children each year across the UK will survive osteosarcoma and go on to live “normal‟ long lives. 

In July 2010, NICE gave initial guidance, which did not recommend Mepact for use on the NHS in England despite a Patient Access Scheme (PAS) being proposed by Takeda. The SMC also gave a negative decision. 

Takeda worked with the Department of Health, NICE and the SMC to find a solution. After three further appraisal committee meetings, NICE acknowledged that to evaluate the health economic value of Mepact accurately, it would need to change its methodology to assess medicines, which improve survival rates beyond 30 years. 

Following a fifth appraisal committee meeting a positive decision for the use of Mepact was given. The SMC also reversed its initial negative decision to recommend the use of Mepact in Scotland.

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics